Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
Numinus Wellness Inc. (NUMIF) is a leader in developing evidence-based psychedelic-assisted therapies for mental health conditions. This dedicated news hub provides investors and stakeholders with centralized access to official updates and strategic developments.
Track critical announcements including clinical trial milestones, regulatory progress, partnership agreements, and financial performance reports. Our curated collection ensures efficient monitoring of Numinus' advancements in depression, anxiety, and trauma treatments through integrated clinic networks and research initiatives.
Key updates cover three strategic pillars: clinical research breakthroughs validating therapeutic protocols, clinic network expansions enhancing patient access, and practitioner training programs ensuring treatment quality. Receive timely alerts on patent filings, research collaborations, and operational optimizations.
Bookmark this page for streamlined tracking of Numinus' progress in transforming mental healthcare through FDA-compliant research and reimbursable treatment models. Visit regularly to stay informed about this innovative leader in psychedelic-assisted therapy development.
Numinus Wellness has submitted a clinical trial application to Health Canada to conduct an experiential training study for therapists in Psilocybin-Assisted Therapy (PAT). The trial will utilize Numinus Bioscience's EnfiniTea for dosing, marking one of the first studies globally on whole Psilocybe mushroom safety. This Phase 1 trial will take place at Numinus' Vancouver clinic and aims to enhance therapist training and knowledge. The results may influence regulatory access to psychedelic-assisted therapies in Canada.
Numinus Wellness reported Q4 2022 revenues of $4.2 million, a 643% increase year-over-year, driven by the acquisition of Novamind. Gross margin improved to 31.5%, resulting in a gross profit of $1.3 million. The company ended the quarter with a cash position of $33.0 million. Fiscal 2022 revenues totaled $6.5 million, marking a 329% increase from the prior fiscal year. Despite significant revenue growth, the company recorded a net loss of $24.7 million in Q4 2022, driven by substantial impairment charges and increased administrative expenses.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will participate in a Water Tower Research Fireside Chat on December 8, 2022, at 11:00 a.m. ET. Founder and CEO Payton Nyquvest will discuss key takeaways from the company's Q4 and Year End 2022 Results, including the impact of their Novamind acquisition and expectations for 2023. Interested participants can register here.
Numinus Wellness will release its financial results for Q4 and the fiscal year ending August 31, 2022, on November 29, 2022, after market close. A conference call will follow at 5:30 p.m. Eastern to discuss performance and initiatives. Interested participants can register for the live webcast or dial in using specified numbers. A replay will be available post-call until December 13, 2022. Numinus focuses on innovative mental health care and psychedelic-assisted therapies, aiming to transform treatment for conditions like depression and anxiety.
Numinus Wellness Inc. has announced the re-launch of its podcast, Psychedelic Therapy Frontiers, aimed at promoting education in psychedelic-assisted therapy. Hosted by experts including Dr. Stephen Thayer, Dr. Reid Robison, and Dr. Joe Flanders, the series will discuss the efficacy of psychedelic treatments for mental health issues like depression and PTSD. New episodes will air every Tuesday across major podcast platforms. This initiative enhances Numinus' commitment to integrating innovative mental health solutions into mainstream practice.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced its participation in the Wonderland conference in Miami from November 3-5, 2022. Dr. Reid Robison, Chief Clinical Officer, will present on the neurobiological differences between classic psychedelics and ketamine on November 5 at 9:50 a.m. ET. Numinus focuses on innovative mental health treatments, facilitating access to safe psychedelic-assisted therapies and aims to integrate these therapies into mainstream clinical practice, addressing conditions like depression and anxiety.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced the launch of its Ketamine for Chronic and Serious Medical Illness Program, aimed at providing ketamine-assisted therapy to patients suffering from terminal conditions and chronic pain. Initially available in clinics across Utah, British Columbia, and Quebec, the program seeks to integrate therapy with existing care to improve overall patient wellbeing. The company is also consolidating its operations following the acquisition of Novamind, aiming for better service delivery and reduced costs.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced that its Founder and CEO, Payton Nyquvest, will participate in a Water Tower Research Fireside Chat on October 13, 2022, at 2:30 p.m. ET. The discussion will center around Numinus' strategic acquisition of Novamind and the growth opportunities it presents. Investors can register here.
On October 5, 2022, Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced the development of a psilocybin-containing tea bag for clinical research and potential therapeutic use. Designed for accessibility, especially for patients needing palliative care, this product allows precise dosing of 25mg per use, made from validated Psilocybe cubensis strains. Numinus aims to include this product in Health Canada's psilocybin supplier list to enhance access to psychedelic-assisted therapies.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF), a leader in mental health care, will participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022, in San Francisco. Founder and CEO Payton Nyquvest will feature in the Digital-Pharma and a New Way of Thinking for NeuroPsych panel on October 7 at 9:00 a.m. PT. Numinus will also partake in a virtual fireside chat during the Cantor Symposium on Mental Health Clinics on October 11, 2022, at 11:00 a.m. ET. The company focuses on innovative, evidence-based psychedelic-assisted therapies aimed at mental health improvement.
FAQ
What is the current stock price of Numinus Wellness (NUMIF)?
What is the market cap of Numinus Wellness (NUMIF)?
